دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Discordance of High-Sensitivity Troponin Assays in Patients With Suspected Acute Coronary Syndromes
J?liaKar?dyMDabThomasMayrhoferPhDacMarosFerencikMD, PhD, MCRadJohn T.NagurneyMD, MPHeJames E.UdelsonMDfAndreas A.KammerlanderMD, PhDagJerome L.FlegMDhW. FrankPeacockMDiJames L.JanuzziJr.MDjWolfgangKoenigMD, PhDklmUdoHoffmannMD, MPHa
doi : 10.1016/j.jacc.2021.01.046
Volume 77, Issue 12, 30 March 2021, Pages 1487-1499
High-sensitivity cardiac troponin (hs-cTn) assays have different analytic characteristics.
Let the Buyer (Clinician) Beware?
Joseph S.AlpertMDaAllanJaffeMDbKristian A.ThygesenMD, DScc
doi : 10.1016/j.jacc.2021.02.031
Volume 77, Issue 12, 30 March 2021, Pages 1500-1502
Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis
PaaladineshThavendiranathanMD, SMa?LiliZhangMD, ScMb?AmnaZafarMDcZsofia D.DrobniMDcdSyed S.MahmoodMD, MPHeMarcellaCabralMDfMagidAwadallaMDcgAnjuNohriaMD, MSchDaniel A.ZlotoffMD, PhDcgFranckThunyMD, PhDijkLucie M.HeinzerlingMD, MPHlmAnaBaracMD, PhDnRyan J.SullivanMDoCarol L.ChenMDpDiptiGuptaMD, MPHpMichael C.KirchbergerMDlSarah E.HartmannBScJonathan W.WeinsaftMDep…Tomas G.NeilanMD, MPHcg
doi : 10.1016/j.jacc.2021.01.050
Volume 77, Issue 12, 30 March 2021, Pages 1503-1516
Myocarditis is a potentially fatal complication of immune checkpoint inhibitor (ICI) therapy. Data on the utility of cardiovascular magnetic resonance (CMR) T1 and T2 mapping in ICI myocarditis are limited.
CMR Parametric Mapping in Immune Checkpoint Inhibitor Myocarditis: Novel Noninvasive Tools in a Lethal Condition?
Christopher M.KramerMDabChristopher A.HansonMDa
doi : 10.1016/j.jacc.2021.01.043
Volume 77, Issue 12, 30 March 2021, Pages 1517-1519
Ultra-Processed Foods and Incident Cardiovascular Disease in the Framingham Offspring Study
FilippaJuulMS, PhDaGeorgetaVaideanMD, MPH, PhDbcYongLinPhDdeAndrea L.DeierleinMS, MPH, PhDfgNiyatiParekhMS, PhD, RDfgh
doi : 10.1016/j.jacc.2021.01.047
Volume 77, Issue 12, 30 March 2021, Pages 1520-1531
Ultra-processed foods provide 58% of total energy in the U.S. diet, yet their association with cardiovascular disease (CVD) remains understudied.
Ultra-Processed Foods and Cardiovascular Disease: Where Do We Go From Here??
Robert J.OstfeldMD, MScaKathleen E.AllenMS, RDb
doi : 10.1016/j.jacc.2021.02.003
Volume 77, Issue 12, 30 March 2021, Pages 1532-1534
Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease
Daniel P.AnderssonMD, PhDaLauraLanducciMDbYlva TrolleLagerrosMD, PhDcdAlessandraGrottaPhDeRinoBelloccoScDefMikaelLehtihetMD, PhDaMartin J.HolzmannMD, PhDcg
doi : 10.1016/j.jacc.2021.01.045
Volume 77, Issue 12, 30 March 2021, Pages 1535-1550
Phosphodiesterase 5 inhibitor (PDE5i) treatment is associated with reduced mortality compared with no treatment for erectile dysfunction after myocardial infarction (MI).
Phosphodiesterase-5 Inhibitors and Survival in Men With Coronary Artery Disease?
RenkeMaasMDaRoman N.RodionovMD, PHDbc
doi : 10.1016/j.jacc.2021.02.021
Volume 77, Issue 12, 30 March 2021, Pages 1551-1553
Statistical Inference in Abstracts Published in Cardiovascular Journals
AndreasStangMD, MPHabMarkusDeckertaSusanneStolpeMSca
doi : 10.1016/j.jacc.2021.01.031
Volume 77, Issue 12, 30 March 2021, Pages 1554-1561
In 2016, the American Statistical Association stated that the use of statistical significance leads to distortion of the scientific process. The principal alternative to significance or null hypothesis testing (NHT) is estimation with point estimates and confidence intervals (CIs).
More Confidence Intervals and Fewer p Values: A Positive Trend??
Jan G.P.TijssenPhD
doi : 10.1016/j.jacc.2021.02.004
Volume 77, Issue 12, 30 March 2021, Pages 1562-1563
New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4
Nick S.NurmohamedMDabAnn MarieNavarMD, PhDcJohn J.P.KasteleinMD, PhDa
doi : 10.1016/j.jacc.2020.11.079
Volume 77, Issue 12, 30 March 2021, Pages 1564-1575
Adding to the foundation of statins, ezetimibe and proprotein convertase subtilisin–kexin type 9 inhibitors (PCSK9i), novel, emerging low-density lipoprotein cholesterol (LDL-C)–lowering therapies are under development for the prevention of cardiovascular disease. Inclisiran, a small interfering RNA molecule that inhibits PCSK9, only needs to be dosed twice a year and has the potential to help overcome current barriers to persistence and adherence to lipid-lowering therapies. Bempedoic acid, which lowers LDL-C upstream from statins, provides a novel alternative for patients with statin intolerance. Angiopoetin-like 3 protein (ANGPTL3) inhibitors have been shown to provide potent LDL-C lowering in patients with homozygous familial hypercholesterolemia without major adverse effects as seen with lomitapide and mipomersen, and may reduce the need for apheresis. Finally, CETP inhibitors may yet be effective with the development of obicetrapib. These novel agents provide the clinician the tools to effectively lower LDL-C across the entire range of LDL-C–induced elevation of cardiovascular risk, from primary prevention and secondary prevention to null-null homozygous familial hypercholesterolemia patients.
Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4
SotiriosTsimikasMDaPatrick M.MoriartyMDbErik S.StroesMD, PhDc
doi : 10.1016/j.jacc.2021.01.051
Volume 77, Issue 12, 30 March 2021, Pages 1576-1589
Lipoprotein(a) [Lp(a)] has risen to the level of an accepted cardiovascular disease risk factor, but final proof of causality awaits a randomized trial of Lp(a) lowering. Inhibiting apolipoprotein(a) production in the hepatocyte with ribonucleic acid therapeutics has emerged as an elegant and effective solution to reduce plasma Lp(a) levels. Phase 2 clinical trials have shown that the antisense oligonucleotide pelacarsen reduced mean Lp(a) levels by 80%, allowing 98% of subjects to reach on-treatment levels of <125 nmol/l (?50 mg/dl). The phase 3 Lp(a)HORIZON (Assessing the Impact of Lipoprotein(a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD) outcomes trial is currently enrolling approximately 7,680 patients with history of myocardial infarction, ischemic stroke, and symptomatic peripheral arterial disease and controlled low-density lipoprotein cholesterol to pelacarsen versus placebo. The co-primary endpoints are major adverse cardiovascular events in subjects with Lp(a) >70 mg/dl and >90 mg/dl, in which either of the two being positive will lead to a successful trial. Additional ribonucleic acid–targeted therapies to lower Lp(a) are in preclinical and clinical development. The testing of the Lp(a) hypothesis will provide proof whether Lp(a)-mediated risk can be abolished by potent Lp(a) lowering.
Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi (No-LVT Trial)
MahmoudAbdelnabiMDYehiaSalehMDAhmedFareedMD, PhDAlexanderNossikofMDLingWangPhDMahmoudMorsiMDNouranEshakMDOlaAbdelkarimMDHaithamBadranMD, PhDAbdallahAlmaghrabyMD
doi : 10.1016/j.jacc.2021.01.049
Volume 77, Issue 12, 30 March 2021, Pages 1590-1592
Spontaneous Coronary Artery Dissection and Cardiogenic Shock: Incidence, Etiology, Management, and Outcomes
CathevineYangMDTakuInoharaMDMesferAlfadhelMDCameronMcAlisterMDAndrewStarovoytovMDDexterChoiBHScG.B. JohnManciniMDEveAymongMDJacquelineSawMD
doi : 10.1016/j.jacc.2021.01.048
Volume 77, Issue 12, 30 March 2021, Pages 1592-1594
Exercise-Induced Pulmonary Hypertension: The Final Answer to Characterize Pulmonary Vascular Disease in Fontan Patients?
HeinerLatusMDChristianApitzMD
doi : 10.1016/j.jacc.2020.12.066
Volume 77, Issue 12, 30 March 2021, Pages 1594-1595
Resist Neglecting Diastolic Dysfunction in Fontan Physiology
AriCedarsMDAlexanderOpotowskyMD, MMScRyan J.TedfordMDDanielBurkhoffMD, PhD
doi : 10.1016/j.jacc.2021.01.036
Volume 77, Issue 12, 30 March 2021, Pages 1595-1596
Reply: Abnormal Pulmonary Vascular Reserve in Fontan: Pulmonary Vascular Disease Versus Diastolic Dysfunction
Alexander C.EgbeMBBS, MPHBarry A.BorlaugMD
doi : 10.1016/j.jacc.2021.01.037
Volume 77, Issue 12, 30 March 2021, Pages 1596-1597
